{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:32Z","timestamp":1793316332229,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.dld.2020.08.041","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:51:47Z","timestamp":1599760307000},"page":"452-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Hepatitis B reactivation and immune check point inhibitors"],"prefix":"10.1016","volume":"53","author":[{"given":"Benoit","family":"Godbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann-Eric","family":"Nisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dld.2020.08.041_bib0001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","article-title":"Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies","volume":"15","author":"Jennings","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"10.1016\/j.dld.2020.08.041_bib0002","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.dld.2019.06.017","article-title":"Hepatotoxicity of immune check point inhibitors: approach and management","volume":"51","author":"Lleo","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"12","key":"10.1016\/j.dld.2020.08.041_bib0003","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.dld.2020.08.041_bib0004","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2020.08.041_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","article-title":"Workup and management of immune\u2010mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment","volume":"25","author":"Hsu","year":"2020","journal-title":"Oncologist"},{"issue":"10088","key":"10.1016\/j.dld.2020.08.041_bib0006","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dld.2020.08.041_bib0007","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.dld.2020.08.041_bib0008","doi-asserted-by":"crossref","first-page":"e19013","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.dld.2020.08.041_bib0009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000434","article-title":"Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series","volume":"28","author":"Kothapalli","year":"2018","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.dld.2020.08.041_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.dld.2020.08.041_bib0011","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00262-020-02521-y","article-title":"Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection","volume":"69","author":"Tsimafeyeu","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.dld.2020.08.041_bib0012","first-page":"1","article-title":"A rare case of pembrolizumab-induced reactivation of hepatitis B","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.dld.2020.08.041_bib0013","doi-asserted-by":"crossref","unstructured":"Lake, A.C.Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy: AIDS2017;31(15):2115\u20138.","DOI":"10.1097\/QAD.0000000000001599"},{"issue":"12","key":"10.1016\/j.dld.2020.08.041_bib0014","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1093\/annonc\/mdx502","article-title":"HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma","volume":"28","author":"Koksal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2020.08.041_bib0015","doi-asserted-by":"crossref","unstructured":"Ragunathan, K., Dadana, S., Huang, C.-H.. Hepatitis B reactivation after administration of pembrolizumab (KEYTRUDA): a unique case report. 2017;112:S1187\u20138.","DOI":"10.14309\/00000434-201710001-02146"},{"issue":"8","key":"10.1016\/j.dld.2020.08.041_bib0016","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/apt.15449","article-title":"Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects","volume":"50","author":"Lombardi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dld.2020.08.041_bib0017","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/liv.14489","article-title":"Immune\u2010related hepatitis related to checkpoint inhibitors: clinical and prognostic factors","volume":"40","author":"Riveiro\u2010Barciela","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.dld.2020.08.041_bib0018","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.dld.2020.08.041_bib0019","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"1","key":"10.1016\/j.dld.2020.08.041_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajco.13050","article-title":"Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection","volume":"15","author":"Kotake","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"issue":"10","key":"10.1016\/j.dld.2020.08.041_bib0021","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.dld.2020.08.041_bib0022","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820304618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865820304618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:14:24Z","timestamp":1761624864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865820304618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1590865820304618"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2020.08.041","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B reactivation and immune check point inhibitors","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2020.08.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}